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Monitoring anaesthetic gas concentrations
in the exhaust of the cardiopulmonary
bypass oxygenator
Editor—Nitzschke and colleagues1 recently studied sevoflur-
ane plasma concentrations during cardiopulmonary bypass
(CPB). The authors found no relationship between sevoflurane
plasma concentrations and either sevoflurane concentrations
in the exhaust of the oxygenator or bispectral index (BIS)
values, prompting them to conclude that ‘Measuring the
concentration of sevoflurane in the exhaust from the oxygen-
ator is not useful for monitoring sevoflurane administration
during bypass’.
However, the authors failed to take into account the conse-
quences of Henry’s law: at aconstant temperature, the amount
of a given gas that dissolves in a given type and volume of liquid
is directly proportional to the partial pressure of that gas in
equilibrium with that liquid. Blood/gas partition coefficient
changes for sevoflurane during CPB were not measured, and
may have been considerable given the acute changes in
blood temperature and haematocrit that routinely occur.2
For this reason, the partial pressure in the blood remains
unknown. This is the important variable, because, like all
gases, inhaled anaesthetics are transported down a partial
pressure gradient (not a concentration gradient), and be-
cause their clinical effects correlate with the partial pressure.
The appropriate technique to use is double headspace equili-
bration of blood samples, as described by many previous
authors, which allows simultaneous measurement of partial
pressure and solubility.3 – 6
To summarize, reporting plasma concentrations without
blood solubility does not allow meaningful clinical recom-
mendations to be made. By implication, trying to find a
relationship between plasma sevoflurane concentration and
BIS with these data is futile. Therefore we argue that the
conclusions by Nitzschke and colleagues are premature:
pending further evidence, it remains reasonable practice to
monitor anaesthetic gas concentrations in the exhaust of the
oxygenator.
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The safety profile of neuraxial magnesium
has not been properly addressed
Editor—We read with interest the recent meta-analysis by Mor-
rison and colleagues,1 in which the authors reviewed the effect
of intrathecal administration of magnesium on the duration of
spinal anaesthesia. After a thorough subgroup analysis, the
authors concluded that the addition of intrathecal magnesium
to lipophilic opioids with or without local anaesthetic is asso-
ciated with an increased duration of spinal anaesthesia in
the non-obstetric population, defined as time to first analgesic
request. They also encouraged authors to perform additional
randomized controlled trials (RCTs) to better define the role
of intrathecal magnesium when administered with local anaes-
thetics alone, and more specifically, in the obstetric population.
However, we would like to raise an important issue. As
stated recently in another meta-analysis investigating the an-
algesic efficacy of perioperative neuraxial magnesium,2 the
safety profile of this mode of administration has not been prop-
erly addressed. This previous review supported the clinical con-
clusions of Morrison and colleagues, demonstrating that
intrathecal magnesium increased the time to first analgesic
request by a mean difference of 39.6 min, reduced morphine
consumption at 24 h after operation, and reduced early post-
operative pain scores. Of concern, however, only four of the
18 included trials, representing a total of only 140 patients,
specifically sought evidence of neurological complications.
Indeed, the bolus doses used of 50–100 mg may be neurotoxic.
Animal studies have demonstrated pain on injection, motor
dysfunction, and histological dose-dependent changes in
rabbit neurones after intrathecal doses of 0.3, 1, 2, and 3 mg
kg21.3 These doses closely mirror human doses studied on a
per kilogram basis (0.7–1.4 mg kg21, based on an estimated
70 kg mass). Moreover, two case reports have described
patients suffering from disorientation4 and continuous peri-
umbilical burning pain5 with continuous infusion of neuraxial
magnesium.
In summary, most human trials investigating the efficacy of
intrathecal magnesium have failed to monitor for neurological
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complications and the potential neurotoxicity of intrathecal
magnesium has not been adequately addressed in animals.
Morrison and colleagues rightly qualify their review with the
caveat that magnesium sulphate is not currently licensed in
the UK for intrathecal administration. We urge cliniciansto con-
sider these concerns. Rather than proceeding with additional
RCTs to answer the questions raised by this meta-analysis,
we advocate additional basic science studies to strengthen
our understanding of the risk-to-benefit balance from the
use of this intrathecal adjunct.
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Reply from the authors
Editor—We thank Dr Albrecht and colleagues for their
thoughtful comments regarding our recent meta-analysis of
the effect of intrathecal magnesium on the duration of spinal
anaesthesia.1 They are justified in raising concerns regarding
the safety of using intrathecal magnesium and, in particular,
of neurotoxicity. We did mention neurotoxicity within the Dis-
cussion section, including the study from Saeki and colleagues2
which demonstrated the destruction of laminae V–VII at
doses of magnesium 1 mg kg21 or more. In contrast, a study
from Chanimov and colleagues3 demonstrated no histological
differences in the spinal cord when serial intrathecal injections
of up to 12.6% magnesium sulphate, lidocaine, or saline were
given to rats.
Other animal studies have also shown conflicting evidence
regarding neurotoxicity. In contrast to Saeki and colleagues,
Simpson and colleagues4 demonstrated that administering
intrathecal magnesium before thoracic aortic cross-clamping
reduced the incidence of paraplegia from spinal cord ischae-
mia in animals. A recent study has shown, however, that in
animals, 15% magnesium sulphate given via the intrathecal
route is associated with some degeneration of the mitochon-
dria, and neuronal degenerative changes on repeated injec-
tions.5 The trials included within our meta-analysis either
used 50% magnesium6 – 9 or 15% magnesium sulphate.10
There were no reported events suggestive of neurotoxicity
within these or any other studies in our meta-analysis, al-
though undoubtedly the length of follow-up may not have
been sufficient to uncover all the possible neurological
effects. Given the inconsistency regarding the potential neuro-
toxicity, we would advocate that the safety profile of magne-
sium sulphate should perhaps be confirmed with further
well-designed safe dose finding studies in clinical research.
Dr Albrecht and colleagues also raise the issue of disorien-
tation after epidural administration of magnesium sulphate
that was administered as an infusion inadvertently.11 We did
not investigate the effect of continuous epidural magnesium
sulphate; hence, we cannot speculate as to whether the symp-
toms are applicable to the intrathecal route. Furthermore, the
authors of the case report attributed the symptoms to a
supra-therapeutic serum magnesium concentration having
received 9 g in just over 1 h.
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